RxDoctor Payments Data

Matthew Wietzke, NP

Psychiatric/Mental Health · San Diego, CANPI 1518613678

Payments from drug & device makers

$1,161in general payments, 2019–2025

Across 40 payments — averaging $29.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$328
  • Teva Pharmaceuticals USA, Inc.$244
  • Indivior Inc.$222
  • Neurocrine Biosciences, Inc.$111
  • Johnson & Johnson$70
  • Otsuka America Pharmaceutical, Inc.$66
  • plus $122 from 3 others

What the payments were for

  • Food & beverage$1,08593%
  • Education$767%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,161 in reported general payments places this provider in the 70th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$7,321
Medicare patients
37
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine12$66,993
Aripiprazole23$2,982
Mirtazapine35$273
Sertraline Hcl39$222
Duloxetine Hcl13$211
Risperidone56$184
Gabapentin26$159
Bupropion Hcl SrBupropion Hcl20$158
Hydroxyzine Pamoate29$155
Buspirone Hcl13$140
Venlafaxine Hcl ErVenlafaxine Hcl27$130
Prazosin Hcl11$106
Trazodone Hcl33$100
Olanzapine11$78
Ramelteon11$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$244$66,99312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →